Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans
On April 1, 2026, the FDA issued a significant policy clarification targeting the most common remaining workaround: compounders and telehealth providers had been adding a secondary ingredient most commonly vitamin B12 to their semaglutide formulations and marketing them as distinct, patient-specific products not subject to the "essentially a copy" prohibition
A history of pregnancy or breastfeeding , medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 will prevent approval
Knowing how to identify red flags and where to obtain legitimate GLP-1 medication can help protect your health and avoid unnecessary risk
Scientific Research Fund of Binzhou Medical University (BY2021KYQD032), National Natural Science Foundation of China (grant number 82200981), Special Funds of Taishan Scholars Project of Shandong Province (grant number tsqn202312384), and the Natural Science Foundation of Shandong Province (grant number ZR2022QH358)